###begin article-title 0
###xml 41 58 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 111 139 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 44 47 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 165 168 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 205 208 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 250 253 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 331 334 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 436 439 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 450 453 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 467 470 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 471 474 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Multiple immune evasion strategies by which HCV establishes chronic infection have been proposed, including manipulation of cytokine responses. Prior infection with HIV increases the likelihood of chronic HCV infection and accelerates development of HCV-related morbidity. Therefore, we investigated in vitro cytokine responses to HCV structural and non-structural proteins in peripheral blood mononuclear cells (PBMC) from uninfected, HIV-infected, HCV-infected and HIV/HCV-coinfected individuals.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 297 298 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 158 161 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 223 226 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 263 266 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 267 270 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 343 346 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 421 424 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 497 500 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 521 524 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 525 528 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 583 586 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 743 746 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 757 760 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 774 777 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 778 781 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 824 827 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 838 841 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 899 902 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 903 906 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 949 952 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Intracellular flow cytometry was used to assess IL-2, IL-10, IL-12, and IFN-gamma production by freshly isolated PBMC incubated for 16 hours with recombinant HCV core, non-structural protein 3 (NS3), and NS4 proteins. Anti-HCV cellular responses were assessed in HIV/HCV-coinfected individuals by 3H-thymidine proliferation assay. Exposure to HCV antigens increased IL-10 production by PBMC, especially in uninfected and HIV-monoinfected individuals. This IL-10 response was attenuated in chronic HCV infection even with HCV/HIV-coinfection. The cells producing IL-10 in response to HCV proteins in vitro matched a PBMC subset recently shown to constitutively produce IL-10 in vivo. This subset was found at similar frequencies in uninfected, HIV-infected, HCV-infected and HIV/HCV-coinfected individuals before exposure to HCV proteins. HCV-specific T cell proliferation was detectable in only one HIV/HCV-coinfected individual who demonstrated no HCV-induced IL-10 response.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 166 169 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
This pattern suggests that selective induction of IL-10 in uninfected individuals and especially in HIV-monoinfected individuals plays a role in establishing chronic HCV infection and conversely, that attenuation of this response, once chronic infection is established, favours development of hepatic immunopathology.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 349 367 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Most viral infections induce cellular and humoral immune responses that act in concert to limit viral spread, clear infection and provide protective immunity against reinfection with the same virus. However, a number of viruses have evolved varied and sophisticated mechanisms to establish persistent infection, even in immunocompetent hosts [1-4]. Epstein-Barr virus (EBV) produces an interleukin-10-like virokine that functionally mimics IL-10 in downregulating cellular immune responses [4].
###end p 9
###begin p 10
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 723 725 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 726 728 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 89 92 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 253 256 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 354 357 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 458 461 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 515 518 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 577 580 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 700 703 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 835 838 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) causes significant morbidity and mortality. Approximately 80% of HCV-exposed individuals develop life-long infection and in many cases, progressive liver disease [5]. Immune escape through mutations introduced by the error prone HCV RNA-dependent RNA polymerase is believed to play a major role in the establishment of persistent HCV infection as strong, broadly directed cellular responses during acute infection are associated with HCV clearance, while narrow, qualitatively impaired anti-HCV responses occur in chronic infection [6-12]. Clearance of HCV after interferon-alpha (IFN-alpha) and ribavirin therapy is also associated with greater breadth and amplitude of anti-HCV cellular immunity [13,14]. These associations suggest that development of appropriate adaptive immune responses relates closely to HCV clearance.
###end p 10
###begin p 11
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 35 38 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 250 253 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 386 389 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 839 842 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1110 1113 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The relatively small RNA genome of HCV encodes few proteins, all of which are involved in some way with virion structure or virus replication. Hence, any immunosuppressive activity must reflect secondary functions of the structural or non-structural HCV proteins. Core, non-structural protein 3 (NS3), NS4 and NS5 have been investigated for a variety of secondary functions. The 20 kDa HCV core protein is associated with cellular transformation in vitro and modulation of cytokine signalling and cellular immune responses [15-17]. The NS3 serine protease downregulates immunoproteosome activity in vitro and may impair immune recognition [18]. NS4 is comprised of NS4A and NS4B, two proteins involved in viral replication. NS4A acts as a cofactor in forming the active protease NS4A/NS3 that participates in polyprotein processing during HCV replication [19], while NS4B is essential for replication and seems to affect the intracellular membranous web where viral replication occurs [20]. NS5A inhibits antiviral PKR activity through its interferon sensitivity determining region (ISDR) [21]. Thus, multiple HCV proteins appear to have evolved secondary functions affecting both innate and adaptive immune responses.
###end p 11
###begin p 12
###xml 349 352 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 387 390 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 401 404 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 418 421 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 422 425 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 530 533 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 576 579 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 645 648 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 750 753 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 816 819 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Viral infection generally triggers production of pro-inflammatory cytokines, but as described above, viruses have evolved gene products that promote persistent infection by tipping the cytokine balance towards immunosuppression. The setting in which viral exposure initially occurs is also relevant, therefore, we compared induction of cytokines by HCV proteins in PBMC from uninfected, HCV-infected, HIV-infected and HIV/HCV-coinfected individuals. Production of the immunosuppressive cytokine IL-10 was selectively triggered by HCV proteins, and the response was greater in HIV-monoinfected and uninfected individuals than in those exposed to HCV. This pattern suggests that selective induction of IL-10 in uninfected individuals and especially in HIV-monoinfected individuals plays a role in establishing chronic HCV infection and conversely, that attenuation of this response, once chronic infection is established, favours development of hepatic immunopathology.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 14
###begin p 15
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 649 651 649 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 102 105 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 119 122 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 123 126 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 145 148 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 285 297 <span type="species:ncbi:9606">participants</span>
###xml 353 356 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 404 407 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 408 411 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 471 474 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 497 500 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 515 518 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 695 698 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 827 830 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 831 834 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 897 900 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 941 944 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
Eight healthy volunteers from St. John's NL, Canada provided blood samples for the study. Twenty-four HIV-infected, 10 HIV/HCV-coinfected, and 3 HCV-infected individuals were also recruited, and Table 1 describes the baseline characteristics of the infected groups. The age and sex of participants was similar across groups. Most individuals exposed to HCV developed chronic infection, although 2 of the HIV/HCV-coinfected individuals had cleared the virus and were anti-HCV antibody positive but HCV RNA negative. HIV related clinical parameters were similar between groups, although there was a statistically nonsignificant trend toward higher CD4+ T cell counts in the coinfected group. Most HIV-infected individuals were on antiviral therapy and had achieved viral suppression at the time of participation. Only one of the HIV/HCV-coinfected individuals had been treated (unsuccessfully) with HCV antiviral therapy, and the remainder of HCV exposed patients were untreated.
###end p 15
###begin p 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end p 16
###begin p 17
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 162 163 162 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 405 406 405 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 137 140 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 221 224 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 246 249 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 361 364 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Abbreviations: Avg average; N/A not applicable; SD standard deviation. 1The time since clinically confirmed infection or, in the case of HCV, high risk activity. 2Undetectable viral load by Roche Amplicor RT-PCR test for HIV and in house PCR for HCV at the time of participation. This also includes those who have spontaneously cleared the virus in the case of HCV. 3Measured on the day of participation. 4Lowest documented count over the course of followup.
###end p 17
###begin title 18
###xml 12 15 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Exposure to HCV proteins induces IL-10 production in PBMC
###end title 18
###begin p 19
###xml 447 448 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 576 577 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 594 595 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 598 599 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 603 604 595 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 608 609 600 601 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 613 614 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 618 619 610 611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 745 747 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 796 798 788 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 987 989 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1141 1142 1133 1134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1146 1148 1138 1140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1192 1194 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1568 1570 1560 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1744 1746 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1854 1856 1846 1848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 1943 1945 1935 1937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2005 2007 1997 1999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 2177 2179 2169 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 2391 2393 2383 2385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 2482 2484 2474 2476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 2792 2794 2784 2786 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 3033 3035 3025 3027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 3107 3109 3099 3101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 3306 3308 3298 3300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 3686 3688 3678 3680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 85 88 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 134 137 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 148 151 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 165 168 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 169 172 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 214 217 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 477 480 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 724 727 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1048 1051 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1069 1072 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1073 1076 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1096 1099 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1307 1310 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1452 1455 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1466 1469 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1483 1486 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1487 1490 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2090 2093 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2126 2129 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2143 2146 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2147 2150 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2332 2335 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2438 2441 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2546 2549 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2672 2675 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2676 2679 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2747 2750 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2861 2864 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2906 2909 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2941 2944 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 2977 2980 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2981 2984 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3072 3075 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3160 3163 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 3226 3229 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3268 3271 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 3330 3333 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3364 3367 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 3368 3371 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3376 3379 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3509 3512 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 3549 3552 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 3611 3614 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To investigate the cytokine response of PBMC from different groups of individuals to HCV proteins, we incubated PBMC from uninfected, HIV-infected, HCV-infected and HIV/HCV-coinfected individuals for 16 hours with HCV core, NS3 and NS4 proteins. Production of IL-2, IL-12, IFN-gamma and IL-10 was then assessed by intracellular flow cytometry. Positive controls for each of these four cytokines demonstrated the efficacy of the antibodies (Figure 1). In no case did any of the HCV antigens, individually or together, induce IL-2, IL-10, IFN-gamma, or IL-12 production (Figure 2). However, IL-10+CD3-CD19-CD14-CD36+CD61+cells with lymphoid light scatter characteristics increased in number following for 16 hours exposure to HCV proteins (Figure 3a, grey bars). We previously described these IL-10+ cells in freshly-isolated PBMC from uninfected individuals, but found that their number fell to almost undetectable levels following 16 hour incubation in unsupplemented lymphocyte medium [22]. All of the individuals in this study (uninfected n = 6, HIV-infected n = 24, HIV/HCV-coinfected n = 10, HCV mono-infected n = 3) had circulating CD36+CD61+ PBMC constitutively producing IL-10 (Figure 3a, black bars). The average percentage of PBMC producing IL-10 ex vivo ranged from 0.37% (range 0.22-0.6%) in the HCV-infected group to 0.75% (range 0.2-1.2%) in the uninfected group. Although there was a trend towards a lower frequency of these cells in the HIV-infected, HCV-infected and HIV/HCV-coinfected groups, there was no statistically significant difference (Figure 3a). As previously described, in the absence of stimulation, the percentage of PBMC producing IL-10 in vitro decreased over time in infected and uninfected individuals (Figure 3a, light grey bars). The uninfected group had the highest frequency of IL-10 producing cells ex vivo (Figure 3a, black bars), however, after for 16 hours incubation in lymphocyte medium alone, IL-10+ cell frequency fell to similar levels in all groups (Figure 3a, light grey bars). The mean frequencies were slightly lower in the uninfected and HCV-infected groups compared to the HIV-infected and HIV/HCV-coinfected groups (Figure 3a, light grey bars, 0.12% and 0.12% versus 0.25%, and 0.24% respectively) but not significantly different. The pattern of IL-10 production in response to HCV proteins differed substantially between groups (Figure 3a, dark grey bars). After 16 hour exposure to HCV proteins, the average frequency of IL-10+ cells rose to 1.63% (n = 12; range 0.1% to 6.6%) in PBMC from HIV-infected individuals, 1.02% (n = 8; range 0.02% to 3%) in uninfected individuals, 0.27% (n = 12; range 0.01% to 1.56%) in HIV/HCV-coinfected individuals, and 0.18% (n = 3; range 0.06% to 0.26%) in HCV-infected individuals. The number of IL-10+ cells detected by flow cytometry following 16 hour exposure to the HCV proteins was significantly higher in the HIV-infected group compared to the HCV-infected (H = 33, p = 0.03) and HIV/HCV coinfected (H = 15.5, p = 0.001) groups (Figure 3a). The effect of 16 hour exposure to HCV proteins on the number of IL-10+ PBMC was quite substantial (5-10 fold increase) in HIV-infected and uninfected control groups, while the increase in HCV-infected individuals, with or without HIV coinfection, was marginal (Figure 3a). If all the chronic HCV-infected individuals from the HIV/HCV and HCV monoinfected groups are combined into one group (n = 13), there is still a significant difference between IL-10 induction in the HIV monoinfected group and the combined HCV chronic infection group (p = 0.016). IL-10 induction when HCV proteins were added together or individually was not different (Figure 3b).
###end p 19
###begin p 20
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Positive controls for cytokine production</bold>
###xml 74 76 70 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 83 85 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 234 236 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 293 295 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Positive controls for cytokine production. (a) IFN-gamma production by CD8+ and CD8- lymphoid gated PBMC after phytohemagglutinin treatment. (b) IL-2 production in total PBMC after PMA/ionomycin treatment. (c) IL-10 production in CD14+ cells after LPS stimulation. (d) IL-12 production in CD14+ cells after LPS stimulation.
###end p 20
###begin p 21
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cytokine production following 16 hour exposure of PBMC to HCV proteins</bold>
###xml 373 375 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 58 61 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 99 102 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 113 116 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 127 130 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 131 134 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Cytokine production following 16 hour exposure of PBMC to HCV proteins. Freshly isolated PBMC from HIV-infected, HCV-infected, HIV/HCV co-infected and uninfected controls were incubated for 16 hours with HCV proteins, then analyzed by intracellular flow cytometry for cytokine production as shown in representative plots. Selective IL-10 production by a small subset of CD3- PBMC with lymphoid scatter characteristics occurred in each case.
###end p 21
###begin p 22
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mean percentage of PBMC from different groups expressing IL-10 ex vivo and following 16 hour incubation with HCV proteins</bold>
###xml 109 112 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 289 292 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 406 409 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 731 734 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 735 738 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 802 805 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Mean percentage of PBMC from different groups expressing IL-10 ex vivo and following 16 hour incubation with HCV proteins. (a) The percentage of IL-10 producing cells (mean +/- SE) was assessed by intracellular flow cytometry in freshly isolated PBMC and following 16 hour incubation with HCV proteins. Black bars represent fresh PBMC, dark grey bars represent PBMC incubated for 16 hours with recombinant HCV core, NS3 and NS4 and lighter grey bars represent the same PBMC incubated for 16 hours with beta-galactosidase control protein. Statistical comparisons are made within groups using the Mann-Whitney U test and between groups using the Kruskal-Wallis test. (b) Representative flow plots of IL-10 production in PBMC from an HIV/HCV-coinfected individual after incubation of PBMC with individual HCV proteins at 2.5 mug/mL. Numbers represent the percentage of IL-10 positive PBMC.
###end p 22
###begin p 23
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 383 385 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 403 407 403 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low </sup>
###xml 418 420 418 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 525 527 525 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo</sup>
###xml 532 535 532 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">lo </sup>
###xml 561 563 561 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi</sup>
###xml 568 571 568 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
There were two clear populations of IL-10 positive cells based on the level of CD36 expression. Approximately 30% of the IL-10 positive cells had a CD36 mean channel fluorescence (MCF) greater than 100, and the remainder were between 10 and 100 (Figure 4a). Cells with higher CD36 mean channel fluorescence (MCF) were more likely to be IL-10 positive, with 100% of CD36hi cells IL-10+ versus 50-70% CD36low cells IL-10+ (Figure 4a). There is a statistically significant difference in the mean channel fluorescence of the CD36loIL-10lo group compared to the CD36hiIL-10hi group (Figure 4b; Fisher's exact test, p < 0.000). This association raises the possibility of a mechanistic link between high CD36 expression and IL-10 production.
###end p 23
###begin p 24
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Relationship between CD36 expression and ex vivo IL-10 production by PBMC</bold>
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 243 245 243 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 265 268 265 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 405 408 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 450 454 450 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">low </sup>
Relationship between CD36 expression and ex vivo IL-10 production by PBMC. (a) Representative flow cytometry plot showing IL-10 production in freshly-isolated CD36+ PBMC cells with lymphoid light scatter characteristics. The percentage of CD36+ cells that are IL-10hi is indicated. (b) Mean channel fluorescence (MCF) for CD36 plotted against IL-10 MCF for six individuals. Open circles represent the CD36hi subset and dark circles represent the CD36low subset as shown in fig. 3a.
###end p 24
###begin title 25
###xml 31 34 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
IL-10 induction is specific to HCV proteins, and independent of T cells and lysosomal antigen processing
###end title 25
###begin p 26
###xml 289 291 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 741 743 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 1119 1121 1116 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1221 1223 1218 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 58 61 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 117 120 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 145 148 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 173 176 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 187 190 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 317 320 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 467 470 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 535 538 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 539 542 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 571 574 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 716 719 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 805 808 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 951 954 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 968 971 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 972 975 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1010 1013 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1163 1166 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1167 1170 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1200 1203 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To determine whether induction of IL-10 was selective for HCV proteins, we also exposed PBMC from 5 uninfected and 5 HIV-infected individuals to HIV p24 protein. Unlike the HCV proteins, HIV p24 did not increase IL-10 production in PBMC relative to the beta-galactosidase controls (Figure 5a, black bars). Therefore, HCV core, NS3 and NS4 selectively induce IL-10 production in PBMC. To confirm that IL-10 induction did not result from endotoxin contamination of the HCV antigen preparations, we incubated PBMC from 5 uninfected and 3 HIV/HCV coinfected individuals with HCV proteins in the presence of polymixin B, an endotoxin blocker. Inclusion of polymixin B in the assays had no effect on induction of IL-10 in HCV-exposed PBMC (Figure 5a, light grey bars). To test whether antigen processing of the HCV proteins was required for induction of IL-10, we inhibited the lysosomal antigen processing pathway with chloroquine in PBMC from uninfected, HIV-infected and HIV/HCV-coinfected individuals exposed to HCV proteins (n = 3, n = 4, n = 4 respectively). Chloroquine treatment did not significantly affect the IL-10+ cell frequency in PBMC from uninfected or HIV/HCV-coinfected groups exposed to HCV proteins (Figure 5b, grey bars with diagonal hatch).
###end p 26
###begin p 27
###xml 0 119 0 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of polymyxin B, chloroquine and T cell depletion on IL-10 production by PBMC exposed to recombinant HCV proteins</bold>
###xml 746 748 741 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 107 110 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 247 250 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 387 390 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 502 505 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 519 522 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 523 526 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 634 637 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 814 817 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Effect of polymyxin B, chloroquine and T cell depletion on IL-10 production by PBMC exposed to recombinant HCV proteins. (a) Cells from uninfected individuals (n = 5) were pretreated with polymyxin B (grey bars) before incubation with recombinant HCV proteins to block the effects of any endotoxin contamination of the recombinant proteins. The effect of 16 hour exposure to recombinant HIV p24 on IL-10 induction was also assessed. (b) The mean percentage PBMC expressing IL-10 (+/- SE) from control, HIV-infected and HIV/HCV coinfected individuals was assessed after exposure to either beta-galactosidase (white background bars) or HCV proteins (grey background bars). Effects of treating PBMC with chloroquine (diagonal hatch) or depleting CD3+ T cells (horizontal hatch) are also shown for comparison with the HCV protein group (grey bars). Each individual was tested on at least 2 different visits.
###end p 27
###begin p 28
###xml 119 121 119 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 10 13 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 79 82 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 171 174 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 262 265 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 358 361 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 375 378 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 379 382 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 495 498 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 626 629 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Since the HCV proteins had the greatest effect on IL-10 induction in PBMC from HIV-infected individuals and reduced CD4+ and total T cell numbers is an integral aspect of HIV infection, we decided to test if the absence of T cells affected the IL-10 response to HCV proteins. Therefore, we depleted CD3+ T cells from the PBMC of 2 individuals in each of the HIV-infected and HIV/HCV-coinfected groups (Figure 5b, horizontal hatch bars) and assessed IL-10 production with and without exposure to HCV proteins (white or grey background bars respectively). The percentage of PBMC producing IL-10 constitutively or in response to HCV proteins was essentially unaffected by T cell depletion after correction for T cell depletion.
###end p 28
###begin title 29
###xml 41 44 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Relationship between IL-10 induction and HCV-specific T cell proliferation
###end title 29
###begin p 30
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6a</xref>
###xml 615 617 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
###xml 743 745 743 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 148 151 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 165 168 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 205 208 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 209 212 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 248 251 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 436 439 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 492 495 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 564 567 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 773 776 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Since IL-10 is an immunomodulatory cytokine that suppresses TH1 type adaptive immunity, we investigated the relationship between IL-10 induction by HCV proteins and HCV-specific T cell proliferation in 10 HIV/HCV-coinfected individuals. A positive HCV-specific proliferation response (stimulation index greater than or equal to 3) was observed in only one individual (018, Figure 6a, black bar), who demonstrated a positive response to HCV core but not NS3 and NS4. After 16 hour exposure to HCV antigens, 6 of the 10 coinfected individuals tested demonstrated an HCV protein-induced increase in the number of IL-10+ cells (grey bars, Figure 6b). Of note, subject 018 was one of the four individuals who did not have increased numbers of IL-10+ cells following exposure to HCV proteins.
###end p 30
###begin p 31
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Anti-HCV cellular responses and IL-10 induction in HIV/HCV coinfected Individuals</bold>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 592 594 587 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 5 8 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 51 54 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 55 58 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 130 133 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 134 137 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 187 190 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 255 258 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 380 383 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 397 400 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 465 468 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 469 472 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 555 558 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 761 764 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 778 781 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Anti-HCV cellular responses and IL-10 induction in HIV/HCV coinfected Individuals. (a) 3H-thymidine incorporation by PBMC from 10 HIV/HCV coinfected individuals incubated for 5 days with HCV core (black bar), NS3 (medium grey bar), NS4 (dark grey bar) or HIV p24 (light grey bar) was measured. A stimulation index of >/=3 was considered positive. Individuals 18 and 150 were anti-HCV positive but HCV RNA negative at the time of testing. (b) IL-10 production in 10 HIV/HCV coinfected individuals after 16 hour incubation with either beta-galactosidase or HCV proteins. The percentage of IL-10+ PBMC within the lymphoid gate is represented on the y axis. Testing was done on the same day as the proliferation data was collected. Individuals 18 and 150 were anti-HCV positive but HCV RNA negative at the time of testing.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 263 265 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 982 984 982 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 36 39 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 845 848 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 886 889 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1014 1017 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1085 1088 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1089 1092 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1119 1122 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1180 1183 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1268 1271 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1308 1311 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1346 1349 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In this study, we demonstrated that HCV core, NS3 and NS4 proteins specifically and selectively induce IL-10 production when incubated for 16 hours with PBMC. The cells producing IL-10 in response to the HCV proteins were identified by flow cytometry as CD14-CD36+ with lymphoid light scatter characteristics. We previously reported constitutive ex vivo production of IL-10 by this PBMC subset and that this production rapidly stops in vitro [22]. These cells do not fit into one of the major subpopulations of circulating immune cells, but can be reliably isolated from all healthy individuals tested at a frequency of up to 1%. The ex vivo frequency of IL-10-producing PBMC was generally equivalent in the four distinct groups we studied, indicating that the differences seen after 16 hour culture were caused by differential responses to the HCV proteins. While 16 hour culture with HCV proteins increased the number of IL-10-producing cells in all groups, the frequency of IL-10+ cells was higher in PBMC from HIV-infected individuals and uninfected controls compared to PBMC from HIV/HCV coinfected individuals or HCV-infected individuals. This demonstrates a propensity for HCV-induced IL-10 production by PBMC from uninfected individuals that is exaggerated by HIV infection and attenuated by chronic HCV infection, even in the setting of HIV coinfection.
###end p 33
###begin p 34
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 363 364 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 368 370 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1221 1223 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1419 1421 1419 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 20 23 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 92 95 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 211 214 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 300 303 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 419 422 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 652 655 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 966 969 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1057 1060 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1080 1084 <span type="species:ncbi:10090">mice</span>
###xml 1108 1111 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1206 1209 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1288 1291 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1312 1315 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We used recombinant HCV core, NS3 and NS4 to investigate cytokine production in response to HCV proteins. Although these three proteins have little sequence or structural similarity and their known functions in HCV replication are very different [23,24], we found that, collectively or individually, HCV core, NS3 and NS4 proteins induced IL-10 production in CD14-CD36+ PBMC. Others have also reported that recombinant HCV core, NS3 and NS4 proteins all induce IL-10 production [16,25,26]. However, in these studies, monocytes were identified as the responding cells and, in direct contrast to our results, there was a greater effect on monocytes from HCV-infected individuals than on monocytes from uninfected controls [16,27]. These studies utilized monocytes isolated by overnight adherence to plastic, rather than freshly isolated PBMC. Despite varying protocols and different characteristics of the responding cells, the central point is that multiple distinct HCV proteins stimulate IL-10 production by PBMC. There are other examples of redundancy in HCV protein effects as mice transgenic for hepatic HCV structural or non-structural polyproteins develop hepatic steatosis characteristic of chronic HCV infection [28]. Such functional redundancy of viral proteins is not unique to HCV, as three different HIV proteins (nef, tat and vpr) have all been reported to induce IL-10 production by various PBMC subsets [29-33].
###end p 34
###begin p 35
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 44 47 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 595 598 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In our study, structural and non-structural HCV proteins induced IL-10. Having both structural and non-structural proteins with redundant immunosuppressive functions may be important in sustaining infection. The availability of these proteins in circulation is temporally separated, and not concurrent. Non-structural proteins are only expressed in actively infected cells, while the core protein can be found in plasma at moderately high levels throughout chronic infection [34,35]. Having multiple proteins that induce IL-10 supports production of an immunosuppressive cytokine whether or not HCV replication is upregulated or infectious virions are present.
###end p 35
###begin p 36
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 533 535 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 640 642 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 807 809 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 810 812 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 996 998 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 999 1001 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1002 1004 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1071 1073 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1074 1076 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1077 1079 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1273 1275 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 35 38 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 84 87 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 324 327 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 376 379 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 413 416 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 645 648 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 713 716 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 815 818 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1007 1010 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1049 1052 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1111 1114 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1263 1266 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1290 1293 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1544 1547 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
In parallel with the redundancy in HCV protein-induced IL-10 production, additional HCV escape mechanisms within both the innate and adaptive immune system have been extensively described. Subversion of the eukaryotic anti-viral interferon-inducible system is a potent evasion strategy employed by many viruses, and several HCV proteins suppress host proteins in this system. HCV E2 inactivates PKR [36], and the HCV serine protease NS3/4a causes proteolysis of Toll-IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) [37], and inhibits phosphorylation of IRF-3, preventing nuclear translocation and IFN-beta gene activation [38]. HCV E2 has also been associated with decreased NK cell function and HCV core stabilizes HLA-E expression and subsequently downregulates NK-mediated cytotoxicity [39-41]. HCV core, E1, NS3, and NS4 are all associated with impaired dendritic cell maturation, thus potentially modulating the function of this integral link to adaptive cellular immunity [16,27,42]. HCV core also downregulates in vitro anti-HCV T cell responses [17,43,44]. While the exact mechanism of HCV protein interaction is unclear, IL-10 inhibits dendritic cell maturation, resulting in an immature phenotype similar to that seen after exposure to HCV core [45]. Not only do HCV proteins modulate immune responses, it is clear that more than one protein has evolved to share similar functions. Production of IL-10 by the cell population described in this paper may stunt dendritic cell maturation, and impair development of anti-HCV cellular immunity through this pathway as well as through a direct effect on responding T cells.
###end p 36
###begin p 37
###xml 456 458 456 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 544 546 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 45 48 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 96 99 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 278 281 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 358 361 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 423 426 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 499 502 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The mechanism for IL-10 induction in PBMC by HCV proteins is unknown, but processing of soluble HCV antigens through the endocytic pathway is unnecessary as blocking antigen processing had no effect on constitutive or induced IL-10 production. A higher percentage of cells from HIV-infected individuals than uninfected controls produced IL-10 in response to HCV proteins. This appears unrelated to lower T cell function in HIV infection as depletion of CD3+ PBMC also did not affect constitutive or HCV-induced IL-10 production by the CD14-CD36+ PBMC.
###end p 37
###begin p 38
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 761 763 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1075 1077 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1197 1199 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 913 916 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 963 966 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1095 1098 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1154 1157 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1202 1205 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The direct correlation between intracellular IL-10 production and intensity of cell surface CD36 expression supports a possible connection between these molecules. Ligands of CD36, a scavenger receptor, include oxidized low density lipoproteins (oxLDL), thrombospondin, collagen types I and IV, apoptotic cells, long chain fatty acids and plasmodium-infected erythrocytes [46-54]. At least 2 of these ligands, thrombospondin and apoptotic cells, have immunosuppressive or anti-inflammatory effects [55,56]. In addition, peroxisomal proliferator associated receptor-gamma (PPAR-gamma) mediated differentiation of monocytes towards a less inflammatory status is accompanied by up-regulation of CD36, which has been used to clinical advantage in cerebral malaria [57]. While there is circumstantial evidence for a link between CD36 and induction of IL-10, there has been no reported evidence of interactions between HCV or any of its individual components and CD36. HCV associates with low density lipoproteins in circulation, and uses the LDL receptor and CD81 to enter cells [58]. CD36 is not an HCV cellular receptor however, recent studies suggest that HCV and the CD36 ligand oxLDL do interact [59]. HCV proteins may indirectly activate IL-10 production through a CD36 related mechanism.
###end p 38
###begin p 39
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1042 1044 1042 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1063 1065 1063 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 79 83 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 190 194 <span type="species:ncbi:11623?0.9953846153846154">LCMV</span>
###xml 276 279 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 410 413 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 870 873 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 952 955 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 999 1002 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1084 1087 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
IL-10 is an important immunomodulatory cytokine, and recent experiments in the LCMV model of chronic viral infection showed that manipulating levels of IL-10 alone was sufficient to dictate LCMV clearance or persistence [60]. However, studies comparing plasma IL-10 levels in HCV-infected and healthy individuals have been less definitive, with some studies describing control levels of serum IL-10 in chronic HCV infection, while other groups describe a marked increase in IL-10 in chronic infection [61-63]. This raises questions about the value of serum IL-10 measurements, as IL-10 has important localized paracrine effects that are not reflected by these generalized IL-10 determinations. As well, none of these studies determine IL-10 levels during acute infection when it may be pivotal in the establishment of chronic infection. We demonstrated that exposure to HCV antigens in chronically infected individuals produced less IL-10 than seen in HCV naive individuals. Longer term exposure to HCV antigens apparently conditions the CD36+ population of IL-10+ cells, attenuating HCV protein specific IL-10 induction. Thus, IL-10 levels during acute infection may be more relevant to the establishment of persistent infection than to maintaining chronic infection.
###end p 39
###begin p 40
###xml 352 354 352 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 37 40 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 147 150 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 241 244 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 365 368 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 487 490 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 573 576 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 583 586 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The transience of IL-10 responses to HCV proteins may allow emergence of cellular immune responses that are pathological in the context of chronic HCV infection. Several studies indicate a protective role for IL-10 in the immunopathology of HCV infection including a clinical trial of exogenous IL-10 administration, accumulation of IL-10 producing CD5+ B cells in HCV-infected individuals with mild disease and an association between high IL-10 gene polymorphism and decreased rates of HCV-related liver fibrosis [64-67]. The diminution in IL-10 induction seen in chronic HCV after HCV protein exposure appears to parallel, and possibly support, insidiously progressive liver disease.
###end p 40
###begin p 41
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 653 655 653 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 733 735 733 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 46 49 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 110 113 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 129 132 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 133 136 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 185 188 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 210 213 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 295 298 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 367 370 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 410 413 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 445 448 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 472 475 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 532 535 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 540 543 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 574 577 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 612 615 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 635 638 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 706 709 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 759 762 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 766 769 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 770 773 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 860 863 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 947 950 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 996 999 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1065 1068 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1069 1072 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1112 1115 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Coinfection with HIV is an important issue in HCV infection because of its relatively high prevalence, higher HCV virus loads in HIV/HCV coinfected individuals and because of increased HCV-related morbidity in HIV coinfected individuals [68-70]. The higher level of IL-10 induction in PBMC from HIV-infected individuals may allow the establishment of more aggressive HCV infection, with downregulation of anti-HCV responses permitting increased HCV replication and higher HCV virus loads. However, this could depend on the order of HCV and HIV infection, with stronger anti-HCV cellular immunity developing when HCV infection precedes HIV-associated CD8+ T cell activation during the asymptomatic phase of HIV infection. Enhanced CD8+ T cell immunity against HCV in HCV/HIV coinfected individuals is likely to accelerate liver disease, while those who acquire HCV following the generalized decline in cellular immunity associated with progressive HIV infection are likely to have especially weak HCV-specific cellular immunity. Thus, there are 2 distinct groups of HIV/HCV coinfected individuals with respect to HCV-specific cellular immunity and its potential role in viral suppression and in the pathogenesis of liver disease.
###end p 41
###begin p 42
###xml 8 11 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 60 63 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 109 112 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 157 160 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 161 164 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 176 182 <span type="species:ncbi:9606">people</span>
###xml 252 255 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 403 406 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 658 661 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Chronic HCV infection mitigates IL-10 production induced by HCV proteins. This is true in the group of three HCV monoinfected individuals, as well as the 10 HIV/HCV coinfected people. Though the monoinfected group is small, the two groups with chronic HCV infection have a total of thirteen individuals, and both have similar results. The limited IL-10 response is even more marked considering that the HIV monoinfected group has the highest IL-10 induction of all groups. Therefore, the lack of IL-10 induction in the setting of chronic infection is likely not an artifact of the small sample size, but a real phenomenon that can even supplant the expected HIV-associated IL-10 induction.
###end p 42
###begin p 43
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 48 51 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 101 104 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 120 123 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 185 188 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 297 300 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Consistent with previous reports, we found that HCV specific T cell proliferation is rare in chronic HCV infection with HIV coinfection a[71,72]. In fact, the only individual with anti-HCV proliferative responses is also one of the individuals with the least number of IL-10 producing cells after HCV protein exposure.
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 419 420 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 424 426 424 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 103 106 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 134 137 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 142 145 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 204 207 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 461 464 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 570 573 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We have demonstrated the presence of a novel population of PBMC that act differentially in response to HCV proteins in uninfected and HIV- or HCV-infected individuals. This differential IL-10 response to HCV antigens is consistent with the generation of an immunoregulatory environment that promotes viral persistence in acute exposure while allowing disease progression in the chronic state. The behaviour of this CD36+CD14- population offers insight into how HCV establishes viral persistence through decreased cellular immune responses and how this is exacerbated by HIV infection.
###end p 45
###begin title 46
Methods
###end title 46
###begin title 47
###xml 6 18 <span type="species:ncbi:9606">Participants</span>
Study Participants
###end title 47
###begin p 48
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 21 24 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 151 154 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 336 341 <span type="species:ncbi:9606">Human</span>
HIV-infected and HIV/HCV-coinfected individuals were recruited from the St. John's General Hospital Infectious Disease Clinic, St. John's, NL, Canada. HCV-infected individuals were recruited from the Capital Health Queen Elizabeth Hospital Hepatitis Clinic in Halifax, NS, Canada. Ethics approval for this project was obtained from the Human Investigation Committee at each institution and all subjects provided informed written consent for blood collection and immunological studies. Uninfected individuals were recruited from Memorial University of Newfoundland Faculty of Medicine personnel.
###end p 48
###begin title 49
###xml 18 21 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Identification of HCV infection
###end title 49
###begin p 50
###xml 0 3 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 55 58 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 156 159 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HCV exposure was ascertained by testing for serum anti-HCV antibodies using second or third generation EIA assays from Ortho Diagnostics (Mississauga, ON). HIV status was determined by commercially available PCR testing by Abbott Diagnostics (Mississauga, ON).
###end p 50
###begin p 51
###xml 111 115 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 145 149 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 31 34 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To demonstrate the presence of HCV RNA, total nucleic acids were extracted from plasma samples, using NucliSens(R) Lysis Buffer and the Nuclisens(R) Isolation Kit (Organon Teknika, Durham, NC). Briefly, 200 muL of plasma was added to 1 mL of lysis buffer. Silica beads were added to bind free nucleic acids, followed by successive washes with 70% ethanol, 95% ethanol, and acetone. Nucleic acids were removed from the silica at 56degreesC with the elution buffer provided. 30 muL of eluant was frozen at -20degreesC if not used immediately for cDNA synthesis.
###end p 51
###begin p 52
###xml 311 317 <span type="species:ncbi:10090">Murine</span>
Complementary DNA (cDNA) was produced from isolated RNA using a first-strand cDNA synthesis kit (Amersham Biosciences, Baie d'Urfe, Quebec). 8 muL of extracted nucleic acid was denatured at 65degreesC for 5 minutes and added to a reaction mix containing random hexamer primer, deoxyribonucleotides, and Moloney Murine Leukemia Virus reverse transcriptase (MMLV-RT). Reactions were placed at 37degreesC for 1 hour followed by MMLV-RT inactivation at 95degreesC for 5 minutes. cDNA was stored at -80degreesC until needed.
###end p 52
###begin p 53
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 408 409 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 101 104 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
cDNA was amplified by polymerase chain reaction (PCR) with primers specific for the highly conserved HCV 5'-untranslated region. Primers and PCR conditions were modified from Shindo et al. [73] as follows: forward primer 5'-GGCGACACTCCACCATAGATC-3' and reverse primer 5'-GGTGCACGGTCTACGAGACCT-3'. The expected amplicon size was 324 bp. Final reactions included 20 mM TRIS-HCl (pH 8.4), 50 mM KCl, 0.5 mM MgCl2, 0.025 U/muL DNA polymerase (Invitrogen, Burlington, Ontario), and 0.5 muM MG18 and MG321 primers (Invitrogen, Burlington, Ontario) in 50 muL. Samples were initially denatured at 95degreesC for 2 minutes, followed by thirty cycles of amplification (95degreesC for one minute, 60degreesC for one minute, and 72degreesC for one minute). PCR products were analyzed on 2% agarose gels with ethidium bromide visualization and stored at -20degreesC.
###end p 53
###begin title 54
PBMC isolation and in vitro stimulation
###end title 54
###begin p 55
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 393 396 393 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
Acid citrate dextrose (ACD) treated whole blood was obtained by venipuncture from each individual and PBMC were isolated by Ficoll-HyPaque Plus (GE Health Care, Baie d'Urfe, PQ, CA) density gradient centrifugation. Cells were washed, counted and suspended at 1 x 106/mL in lymphocyte medium (RPMI supplemented with 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 1% penicillin/streptomycin, and 2 x 10-5 M 2-mercaptoethanol; all from Invitrogen, Burlington, ON, CA).
###end p 55
###begin p 56
###xml 95 97 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 1175 1177 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 27 30 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 277 280 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 358 361 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 770 773 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
###xml 802 805 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 833 840 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1331 1334 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
To determine the effect of HCV proteins on PBMC from healthy and infected individuals, 1.5 x 106 freshly isolated PBMC were incubated in lymphocyte medium at 37degreesC for 16 hours with 10 mug/mL Brefeldin A (Sigma Chemical Co., St. Louis, MO, USA) and 2.5 mug/mL recombinant HCV core, NS3, and NS4 proteins (Virogen, Watertown, MA), 2.5 mug/mL recombinant HIV p24 from the same source (Virogen) or 2.5 mug/mL various control proteins. Initially, various concentrations (1, 2.5, 5, and 7.5 mug/mL) were tested in 3 individuals to determine if there was a dose response. All concentrations tested demonstrated results within 0.01% of each other in each individual (data not shown), and 2.5 mug/mL was used in subsequent studies as it was compareable to other studies of HCV proteins in human PBMC. The HCV antigens were expressed in E. coli as beta-galactosidase fusion proteins, and supplied in a urea-based buffer, therefore, negative controls included beta-galactosidase (Calbiochem, La Jolla, CA) in the same buffer as the viral antigens. Polymixin B sulfate (PMB; Sigma) was added at 100 mug/mL to block any endotoxin-induced cytokine production as described previously[74]. For some experiments, the lysosomal antigen processing pathway inhibitor chloroquine (Sigma) was added at 50 muM to PBMC 30 minutes before addition of HCV antigens to investigate whether antigen processing was involved in IL-10 induction. Cytokine production was assessed by intracellular flow cytometry.
###end p 56
###begin title 57
T cell depletion
###end title 57
###begin p 58
###xml 25 27 25 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 437 439 431 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 610 613 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 618 621 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For some experiments, CD3+ T cells were removed from fresh PBMC by depletion with magnetic beads. Ten million fresh PBMC were washed and resuspended in cold depletion buffer (PBS supplemented with 5 mM EDTA and 0.5% BSA) at 3 x 106/mL, and a 10:1 bead-to-target cell ratio with mouse anti-human CD3-coated magnetic beads (Dynal ASA, Lake Success, NY). Cells and beads were rotated together for 45 minutes at 4degreesC, and bead bound CD3+ cells were removed using a magnet. Depletion efficiency was >97% as determined by flow cytometry. The remaining cells were resuspended in lymphocyte medium and exposed to HCV and HIV proteins as described above.
###end p 58
###begin title 59
Flow cytometry
###end title 59
###begin title 60
Surface staining
###end title 60
###begin p 61
###xml 915 917 909 911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 989 995 <span type="species:ncbi:9913">bovine</span>
PBMC subpopulations were phenotyped by surface and intracellular flow cytometry using the following antibodies: CD3-phycoerythrin (PE; Clone UCHT1, DakoCytomation, Mississauga, ON), CD4-fluorescein isothiocyanate (FITC; Clone RPA-T4, BD Pharmingen, San Diego, CA), CD8-peridinin chlorophyll (PerCP; Clone RPA-T8, BD Pharmingen), CD14-FITC or CD14-PE (Clone M5E2, BD Pharmingen), CD36-PE (Clone CB38, BD Pharmingen), CD19-FITC (Clone HIB19, BD Pharmingen), CD56-FITC (Clone HA58, BD Pharmingen) and CD61-PerCP (clone VI-PL2, BD Pharmingen). To each tube, IL-10 and CD36 were added, along with one other surface marker for each major cell type (e.g. CD36, IL-10, and CD3). Through this strategy, 3 color flow cytometry was used to identify the cell population of interest. All steps were performed at 4degreesC, and incubations were carried out in the dark to prevent fluorochrome photobleaching. Approximately 5 x 105 PBMC were washed with flow cytometry buffer (PBS supplemented with 0.1% bovine serum albumin (BSA), 5 mM EDTA and 0.02% sodium azide, all from Sigma), resuspended in 600 muL and incubated for 20 minutes with 0.5 mug antibody against surface antigens or appropriate isotype controls. Cells were washed, fixed with 0.5 mL 1% paraformaldehyde (Sigma) for 20 minutes, resuspended in 250 muL of 1% paraformaldehyde, and stored at 4degreesC until analysis on a FACScan flow cytometer (Becton Deckinson). CellQuest Protrade mark and WinMDItrade mark were used for data analysis.
###end p 61
###begin title 62
Intracellular staining
###end title 62
###begin p 63
Cells were stained as above for surface antigens with an additional permeabilization step after fixation. Cells were incubated with either 0.5 mL 0.2% saponin (Sigma) in PBS or DAKO permeabilization reagent and anti-IL-10 FITC (clone JES9D7 Caltag, Burlingame, CA), anti-IFN-gamma FITC, (clone B27, Caltag), anti-IL-2 FITC, (clone MQ1-17H12 Caltag) anti-IL-12 FITC (clone C8.6 Caltag) antibodies or appropriate isotype controls for 20 minutes at 4degreesC in the dark. After washing with 3 mL flow buffer, cells were resuspended in 1% paraformaldehyde until analysis.
###end p 63
###begin p 64
Total PBMC were incubated for 16 hours with either 5 mug/mL phytohemagglutinin, 10 nM phorbol 12-myristate 13-acetate (PMA)/100 nM ionomycin, or 200 ng/mL lipopolysaccaride to provide positive controls for IFN-gamma, IL-2, IL-10, and IL-12 production, respectively. Brefeldin A was added one hour after the various stimulants. Lymphoid cells were gated and stained for CD8 and IFN-gamma production, total PBMC for IL-2 production, and monocytes were gated for IL-12 and IL-10 production.
###end p 64
###begin title 65
Proliferation assays
###end title 65
###begin p 66
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 546 547 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 791 792 787 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 166 171 <span type="species:ncbi:9606">human</span>
###xml 399 415 <span type="species:ncbi:5476">Candida albicans</span>
###xml 467 470 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 489 492 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cellular immune responses were measured by standard 5 day thymidine incorporation assay. PBMC were washed twice with proliferation medium (lymphocyte medium with 10% human AB serum (Atlanta Biologicals, lot number M0102) substituted for FBS) and 1 x 105 cells/well were incubated in triplicate with either plain medium, 5 mug/mL phytohemagglutinin (ICN Biomedicals Inc., Costa Mesa, CA), 2.5 mug/mL Candida albicans (Greer Laboratories Inc., Lenoir, NC), or 2 mug/mL HCV core, NS3, NS4 or HIV p24 (all Virogen) for 5 days. One muCi of tritiated (3H)-thymidine (Perkin Elmer Life Sciences, Boston, MA) was added to each well on day 4, and the assay was harvested onto glass fiber mats 18 hours later using a semi-automated harvester (Tomtec Harvester 96 Mach M III, Hamden, CT). Incorporated 3H-thymidine was measured by a 96 well scintillation counter (TopCount, Packard, Meriden, CT). Stimulation indices were calculated as follows:
###end p 66
###begin p 67

###end p 67
###begin title 68
Statistical Analyses
###end title 68
###begin p 69
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
All statistical analyses were performed using SPSS version 9 (SPSS Inc., Chicago, IL). In figure 2, the group sizes were small and unequal. Therefore, nonparametric tests were used to compare means. Within a group, the Mann-Whitney U test was used, while the Kruskal-Wallis test was used to test for differences between groups, as there were greater than 3 groups. Neither test depends on the data distribution for calculation, and the Kruskal-Wallis for multiple comparisons adjusts the alpha value to avoid inflation of type I error. In figure 3, the Fisher's exact test was used to compare the categorical data. All graphs indicate mean values and error bars represent standard error of the mean.
###end p 69
###begin title 70
Authors' contributions
###end title 70
###begin p 71
###xml 202 210 <span type="species:ncbi:9606">patients</span>
LB designed and carried out the experiments, and drafted the manuscript. MGa carried out some of the proliferation assays. CH, MIB, GH, and KP participated in the design of the study and recruitment of patients. MG designed and coordinated the study, and drafted the manuscript.
###end p 71
###begin title 72
Acknowledgements
###end title 72
###begin p 73
We greatly appreciate the participation of clients from the Infectious Diseases Clinic in St. John's NL as well as that of clients of the Hepatitis Clinic in Halifax, NS. Thanks to Ian Bradbury for helpful discussion on the statistical treatments, Jessica Rose (PHA and PMA/ionomycin) and Chris Little (IL-12 and IL-10) for assistance with the positive cytokine controls. This research was supported by the Canadian Institutes of Health Research (CIHR) and Health Canada through an operating grant to MG (EOP41541) and a CIHR MD/PhD scholarship awarded to LB.
###end p 73
###begin article-title 74
Viral mechanisms of immune evasion
###end article-title 74
###begin article-title 75
Anti-immunology: evasion of the host immune system by bacterial and viral pathogens
###end article-title 75
###begin article-title 76
###xml 60 74 <span type="species:ncbi:10245">vaccinia virus</span>
An investigation of incorporation of cellular antigens into vaccinia virus particles
###end article-title 76
###begin article-title 77
###xml 51 69 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines
###end article-title 77
###begin article-title 78
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
Hepatitis C: the clinical spectrum of disease
###end article-title 78
###begin article-title 79
###xml 43 50 <span type="species:ncbi:9606">persons</span>
###xml 65 82 <span type="species:ncbi:11103">hepatitis C virus</span>
Analysis of successful immune responses in persons infected with hepatitis C virus
###end article-title 79
###begin article-title 80
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 85 96 <span type="species:ncbi:11103">hepatitis C</span>
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
###end article-title 80
###begin article-title 81
###xml 38 55 <span type="species:ncbi:11103">hepatitis C virus</span>
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
###end article-title 81
###begin article-title 82
###xml 61 78 <span type="species:ncbi:11103">hepatitis C virus</span>
Determinants of viral clearance and persistence during acute hepatitis C virus infection
###end article-title 82
###begin article-title 83
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 77 94 <span type="species:ncbi:11103">hepatitis C virus</span>
Broad specificity of virus-specific CD4+ T-helper cell responses in resolved hepatitis C virus infection
###end article-title 83
###begin article-title 84
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 34 51 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 95 106 <span type="species:ncbi:11103">hepatitis C</span>
Detection of functionally altered hepatitis C virus-specific CD4+ T cells in acute and chronic hepatitis C
###end article-title 84
###begin article-title 85
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 81 98 <span type="species:ncbi:11103">hepatitis C virus</span>
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
###end article-title 85
###begin article-title 86
###xml 70 81 <span type="species:ncbi:11103">hepatitis C</span>
Effects of antiviral therapy on the cellular immune response in acute hepatitis C
###end article-title 86
###begin article-title 87
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 137 154 <span type="species:ncbi:11103">hepatitis C virus</span>
Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection
###end article-title 87
###begin article-title 88
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation
###end article-title 88
###begin article-title 89
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation
###end article-title 89
###begin article-title 90
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway
###end article-title 90
###begin article-title 91
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity
###end article-title 91
###begin article-title 92
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
Replication of hepatitis C virus
###end article-title 92
###begin article-title 93
###xml 14 31 <span type="species:ncbi:11103">hepatitis C virus</span>
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex
###end article-title 93
###begin article-title 94
###xml 33 50 <span type="species:ncbi:11103">hepatitis C virus</span>
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation
###end article-title 94
###begin article-title 95
Circulating CD14-CD36+ peripheral blood mononuclear cells constitutively produce interleukin-10
###end article-title 95
###begin article-title 96
###xml 22 39 <span type="species:ncbi:11103">hepatitis C virus</span>
Structural biology of hepatitis C virus
###end article-title 96
###begin article-title 97
Virology of hepatitis B and C viruses and antiviral targets
###end article-title 97
###begin article-title 98
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
###xml 19 22 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 144 147 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection
###end article-title 98
###begin article-title 99
###xml 34 37 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms
###end article-title 99
###begin article-title 100
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes
###end article-title 100
###begin article-title 101
###xml 30 45 <span type="species:ncbi:10090">transgenic mice</span>
###xml 102 119 <span type="species:ncbi:11103">hepatitis C virus</span>
Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus
###end article-title 101
###begin article-title 102
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr impairs dendritic cell maturation and T-cell activation: implications for viral immune escape
###end article-title 102
###begin article-title 103
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 164 169 <span type="species:ncbi:9606">human</span>
Intracellular HIV-Tat expression induces IL-10 synthesis by the CREB-1 transcription factor through Ser133 phosphorylation and its regulation by the ERK1/2 MAPK in human monocytic cells
###end article-title 103
###begin article-title 104
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway
###end article-title 104
###begin article-title 105
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Monocytes are target cells for IL-10 induction by HIV-1 Nef protein
###end article-title 105
###begin article-title 106
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway
###end article-title 106
###begin article-title 107
###xml 44 61 <span type="species:ncbi:11103">hepatitis C virus</span>
Recent advances in the molecular biology of hepatitis C virus
###end article-title 107
###begin article-title 108
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
###end article-title 108
###begin article-title 109
###xml 61 64 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
###end article-title 109
###begin article-title 110
###xml 18 35 <span type="species:ncbi:11103">hepatitis C virus</span>
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF
###end article-title 110
###begin article-title 111
###xml 52 69 <span type="species:ncbi:11103">hepatitis C virus</span>
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease
###end article-title 111
###begin article-title 112
###xml 75 92 <span type="species:ncbi:11103">hepatitis C virus</span>
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein
###end article-title 112
###begin article-title 113
###xml 15 32 <span type="species:ncbi:11103">hepatitis C virus</span>
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions
###end article-title 113
###begin article-title 114
###xml 37 40 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells
###end article-title 114
###begin article-title 115
###xml 85 102 <span type="species:ncbi:11103">hepatitis C virus</span>
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
###end article-title 115
###begin article-title 116
###xml 59 76 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 104 121 <span type="species:ncbi:11103">hepatitis C virus</span>
Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence
###end article-title 116
###begin article-title 117
###xml 4 21 <span type="species:ncbi:11103">hepatitis C virus</span>
The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations
###end article-title 117
###begin article-title 118
###xml 92 109 <span type="species:ncbi:11103">hepatitis C virus</span>
Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection
###end article-title 118
###begin article-title 119
###xml 47 68 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance
###end article-title 119
###begin article-title 120
Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor
###end article-title 120
###begin article-title 121
Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells
###end article-title 121
###begin article-title 122
CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis
###end article-title 122
###begin article-title 123
###xml 56 61 <span type="species:ncbi:9606">human</span>
CD36 is required for phagocytosis of apoptotic cells by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v beta 3)
###end article-title 123
###begin article-title 124
Analysis of CD36 binding domains: ligand specificity controlled by dephosphorylation of an ectodomain
###end article-title 124
###begin article-title 125
Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion
###end article-title 125
###begin article-title 126
Isolation of the thrombospondin membrane receptor
###end article-title 126
###begin article-title 127
CD36 is a receptor for oxidized low density lipoprotein
###end article-title 127
###begin article-title 128
A role for CD36 in the regulation of dendritic cell function
###end article-title 128
###begin article-title 129
###xml 55 60 <span type="species:ncbi:9606">human</span>
Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation
###end article-title 129
###begin article-title 130
###xml 118 139 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages
###end article-title 130
###begin article-title 131
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
Binding of hepatitis C virus to CD81
###end article-title 131
###begin article-title 132
###xml 42 59 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
###end article-title 132
###begin article-title 133
Interleukin-10 determines viral clearance or persistence in vivo
###end article-title 133
###begin article-title 134
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 88 99 <span type="species:ncbi:11103">hepatitis C</span>
Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection
###end article-title 134
###begin article-title 135
###xml 38 55 <span type="species:ncbi:11103">hepatitis C virus</span>
Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa
###end article-title 135
###begin article-title 136
###xml 45 56 <span type="species:ncbi:11103">hepatitis C</span>
Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment
###end article-title 136
###begin article-title 137
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 67 78 <span type="species:ncbi:11103">hepatitis C</span>
Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders
###end article-title 137
###begin article-title 138
###xml 44 55 <span type="species:ncbi:11103">hepatitis C</span>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect
###end article-title 138
###begin article-title 139
###xml 33 50 <span type="species:ncbi:11103">hepatitis C virus</span>
Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism
###end article-title 139
###begin article-title 140
###xml 57 74 <span type="species:ncbi:11103">hepatitis C virus</span>
Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection
###end article-title 140
###begin article-title 141
###xml 30 47 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 82 110 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy
###end article-title 141
###begin article-title 142
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 77 88 <span type="species:ncbi:11103">hepatitis C</span>
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol
###end article-title 142
###begin article-title 143
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Mortality for liver disease in patients with HIV infection: a cohort study
###end article-title 143
###begin article-title 144
###xml 20 31 <span type="species:ncbi:11103">hepatitis C</span>
###xml 40 51 <span type="species:ncbi:11103">hepatitis C</span>
###xml 64 81 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients
###end article-title 144
###begin article-title 145
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
###xml 36 53 <span type="species:ncbi:11103">hepatitis C virus</span>
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses
###end article-title 145
###begin article-title 146
###xml 18 29 <span type="species:ncbi:11103">hepatitis C</span>
###xml 84 95 <span type="species:ncbi:11103">hepatitis C</span>
Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C
###end article-title 146
###begin article-title 147
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human monocyte CD14 is upregulated by lipopolysaccharide
###end article-title 147

